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METHODOLOGICAL ISSUES—Risk Assessment
Studies
PMD44
ADVANCING RISK ADJUSTMENT FOR
SCHIZOPHRENIA
Martin BC, Dorfman JH, Miller LS, Kotzan JA
University of Georgia, Athens, GA, USA
OBJECTIVE: The objective of this study was to develop
and validate a series of schizophrenia speciﬁc risk adjust-
ment cost models. METHODS: Georgia Medicaid claims
data linked with institutional inpatient data for 21,602
continuous eligible persons suffering from schizophrenia
was used to build a prospective diagnosis-based, a demo-
graphic-based, a drug-based, and a combined risk ad-
justment cost model. ICD-9-CM and drug category
classiﬁcations were derived from the literature and sup-
plemented by an expert panel. Variables were screened
and cost weights were derived empirically in a random
50% training sample using a robust a weighted Heuber-
White regression model and validated by expert panel
review, bootstrapping methods, and assessing indices of
discrimination in a 50% validation sample. Model cali-
bration and correlations of errors with policy relevant
groups were also estimated. RESULTS: Measures of dis-
crimination (R2) varied between 16.4% for the ICD-9-
CM based model to 21.8% for the combined model for
trimmed total cost and varied between 4.9% to 11.3%
for mental health costs in the validation sample. Risk
adjustment models based on drug or ICD-9-CM infor-
mation discriminated costs equally well and the combined
models outperformed both drug and ICD-9-CM based
models. A simple model using prior year costs combined
with demographic covariates had R2s > 40% for both
mental health and total costs. CONCLUSIONS: The drug
and ICD-9-CM based models performed equally well and
either can be used with equal conﬁdence depending on
data availability. The combined models performed better
than either the ICD-9-CM or drug based models indicat-
ing that drug exposure information can compliment more
traditional approaches. Health services researchers
wishing to control for differences in comorbidity and
severity that inﬂuence cost should always consider includ-
ing prior utilization (costs) since prior year costs were
vastly superior predictors of costs.
PMD45
OUTCOMES RESEARCH AND PHASE 1–2
PHARMACEUTICAL RISK ASSESSMENT
Lockett AE
Covance, Leeds, United Kingdom
OBJECTIVES: To determine the most effective way to
determine risk beneﬁt ratios in phase 1–2 developmental
compounds. The EMEA and FDA have recently published
discussion documents on the need to incorporate an
assessment of risk beneﬁt ratios during pharmaceutical
development. While methods are established for the
formal analysis of later stage development, the method to
assess risk in early development is unclear. This paper
seeks to identify what methods are available and assess
their application to risk-beneﬁt assessment in early stage
products. METHODS: A literature review of the methods
used to assess new technology risks. The nature of the
risks involved in early stage (phase 1 and 2) pharmaceu-
tical development were also identiﬁed from a database,
and the core values of the risks determined by established
frameworks. RESULTS: Four main methods were deter-
mined: formal analysis, bootstrapping, trade off and,
judgement analysis. In the analysis of the nature of the
risks of phase 1/2 pharmaceutical development much of
the risk can be described as voluntary risk, due to the
informed consent process. The acceptance of risk will
therefore vary with the severity of the condition and the
equity of the treatment being offered. The remainder of
the risk is outcome related, and so needs to be viewed in
the context of the aims of treatment. Comparing the
methods used to assess risk, only Judgement Analysis was
able to incorporate the degree of voluntary risk encoun-
tered in the risk assessment of pharmaceuticals in early
development. CONCLUSIONS: The ﬁnding that Judge-
ment Analysis is the only method to assess risk beneﬁt in
early stage development is controversial as it runs against
the statistical methods favoured by the regulators. The
results indicate a strong need to educate ethics commit-
tees and other clinical trial professionals in a wider range
of outcomes research.
PMD46
PROCESS UTILITY DERIVED FROM PROVIDING
INFORMAL CARE
Brouwer WBF1,Van Exel J2,Van den Berg B2,
Koopmanschap M1
1Erasmus University Rotterdam, Rotterdam, Netherlands;
2Erasmus Medical Centre Rotterdam, Rotterdam, Netherlands
OBJECTIVES: Though economics is usually outcome-
oriented, it is often argued that processes matter as well.
Utility is not only derived from outcomes, but also from
the way this outcome is accomplished. Providing care on
a voluntary basis may especially be associated with such
process utility. In this paper we discuss the process utility
from providing informal care. We test the hypothesis that
informal caregivers derive utility not only from the
outcome of informal care, i.e. that the patient is ade-
quately cared for, but also from the process of providing
informal care. METHODS: We measure process utility as
the difference in utility between the current situation in
which the care recipient is cared for by the caregiver and
the hypothetical situation that someone else takes over
the care tasks, all other things equal. We present empiri-
cal evidence of process utility on the basis of a large
sample of Dutch caregivers (n = 950) and analyse these.
RESULTS: Our results show that process utility exists
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and is substantial and therefore important in the context
of informal care. Almost half of the caregivers (48.2%)
derive positive utility from informal care and on average
happiness would decline if informal care tasks were
handed over to someone else. The multivariate analysis
shows that process utility is signiﬁcantly related to,
amongst other things, age and gender of the caregiver.
Male caregivers have lower process utility than female
caregivers. Closer relationship (partner, parent, child)
elicit lower process utility than others. CONCLUSIONS:
Process utility is impotant in the context of informal care.
Our results strengthen the idea of supporting informal
care, but also that of keeping a close eye on the position
of carers.
METHODOLOGICAL ISSUES—Utility Studies
PMD47
CALCULATING UTILITY VALUES FROM SF-36:
A COMPARISON OF DIFFERENT ALGORITHMS
Svensson K
AstraZeneca R&D Lund, Sweden, Lund, Sweden
OBJECTIVES: This study aims to investigate if the results
of four published algorithms for calculating utility values
from assessments of SF-36 are in agreement with the
responses of traditional efﬁcacy variables assessed in a
randomized clinical study with different treatments of
asthmatic patients. METHODS: Data from a randomized
clinical study of moderate asthmatic patients comparing
treatment with budesonide alone (n = 114) with budes-
onide plus formoterol (n = 109) during 12 weeks are used
in this investigation. Utility values from the four algo-
rithms are calculated for the different treatment groups
at randomization and at end of treatment, and both
absolute values as well as change during treatment are
correlated with efﬁcacy variables assessed in the study:
PEF Morning, FEV1, and the summary score SF-36 PCS
from the SF-36 questionnaire. RESULTS: Mean Utility
values at baseline range between 0.61 to 0.82 for the 4
algorithms but with no difference between the two treat-
ment groups. Change during treatment varies between
0.08 and 0.11. While both PEF Morning and FEV1 are
statistically signiﬁcant when comparing the change during
treatment between the two treatment groups, neither any
of the SF-36 domains nor SF-36 PCS turns out to be. Two
out of the four utility measures, both based on TTO,
reaches statistical signiﬁcance. Correlation for change
during treatment shows moderate correlation with PEF
Morning (0.28 to 0.32) and FEV1 (0.17 to 0.25). CON-
CLUSION: The two utility measures based on the SF-36
items (or a subset thereof) and evaluated through TTO
show better response than the other two, one evaluated
through a Visual Analog Scale as rating scale, and the
other based on domain values and not item values from
SF-36.
PMD48
RELATIVE WEIGHTS ASSIGNED TO DRUGS AND
BIOLOGICALS: OPPS METHODS AND
CONCEPTS
Baker JJ
University of Rochester, Pickton,TX, USA
OBJECTIVE: The Centers for Medicare and Medicaid
Services (CMS) assigns a relative weight to those high 
cost new technology drugs designated with a non-
pass-through or expired pass-through payment status.
This study examines the conceptual approach of relative
weights for drugs and biologicals under the CMS Hospi-
tal Outpatient Prospective Payment System (OPPS) and
compares this approach to the resource-based level of
effort concept initially created for payment to physicians’
ofﬁces in the U.S. METHODS: The underlying intent of
relative value units (RVUs) in the physician’s ofﬁce was
to create a hierarchy of resource-based level of effort
involved in various types of ofﬁce-based service delivery.
The concept of hospital OPPS was also intended to reﬂect
resource-based services. Thus the OPPS relative weights
should be related to resource-based levels of effort. 
Non-pass-through high cost new technology drugs that
are paid separately under OPPS are assigned a relative
weight, implying that the payment includes level of effort
resources. We postulate these relative weights contain no
such level of effort, but instead represent only the pure
drug component. This use of the relative weight concept
distorts its initial intent. RESULTS: Resource-based
methods initially proposed for the hospital OPPS were
collected and deconstructed. CMS rationale supporting
treatment of non-pass-through high cost new technology
drugs paid separately under OPPS was identiﬁed. CMS
drug payment computation methods were likewise decon-
structed and evaluated. The evaluation sought indications
of resource-based level of effort applications. CONCLU-
SIONS: Many researchers and policy makers assume that
relative weights equate to level of effort resource con-
sumption in all instances. We cannot ﬁnd this is so in the
case of non-pass-through high cost new technology drugs
paid separately under OPPS. It is necessary to draw CMS
attention to this issue, as the volume of forthcoming new
drugs and biologics means the issue will become increas-
ingly important.
